

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SUNSHINE LAKE PHARMA CO., LTD.

廣東東陽光藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6887)

**VOLUNTARY ANNOUNCEMENT
ENTERING INTO A STRATEGIC COOPERATION
FRAMEWORK AGREEMENT**

This announcement is made by Sunshine Lake Pharma Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis. The board of directors of the Company (the “**Board**”) is pleased to announce that a strategic cooperation agreement (the “**Strategic Cooperation Agreement**”) has been entered into between the Company and Shenzhen XtalPi Technology Co., Ltd. (“**Shenzhen XtalPi**”) on 26 January 2026.

According to the Strategic Cooperation Agreement, both parties intend to establish a joint venture to jointly build an AI-driven drug research and development platform, focusing on the following cooperation:

(1) ESTABLISHMENT OF A JOINT LABORATORY FOR THE COLLABORATIVE DEVELOPMENT OF INNOVATIVE DRUG PIPELINES

Both parties will establish a joint laboratory aimed at achieving AI-driven automation, leveraging Shenzhen XtalPi’s automated experimental platform technology and deployment expertise, which will create a “Design-Build-Test-Learn” R&D closed-loop. Focusing on autoimmune diseases, the parties will jointly discover drug candidates, which will then be advanced by the joint venture.

(2) JOINT DEVELOPMENT AND PROMOTION OF LARGE MODELS

Based on the Company’s multi-target and high-quality non-clinical data, the parties will integrate Shenzhen XtalPi’s AI algorithm platform and large model training capabilities to develop a predictive PBPK large model that benchmarked against industry-leading mainstream commercial software, and jointly build an AI drug R&D engine covering the entire drug development lifecycle.

Leveraging Shenzhen XtalPi’s global commercial network and expertise in AI platform productization, the parties will promote the Group’s proprietary “HEC-SynAI Drug Synthesis Large Model” and “HEC-PharmAI Formulation Large Model,” as well as the new-generation PBPK large model.

(3) ESTABLISHMENT OF “MODEL-AS-A-SERVICE” (MAAS) BUSINESS MODEL

The parties plan to jointly establish an AI supercomputing platform under a “computational power support + data development + ecosystem sharing” model, opening collaborative achievements to both academia and industry, and transform data assets and AI products into a “Model-as-a-Service” (MaaS) business model.

The Board believes that the Strategic Cooperation Agreement provides a valuable opportunity for both parties to leverage their resources and expertise to create mutual benefits and synergies. Therefore, the Board believes that the entering of the Strategic Cooperation Agreement is in the interests of the Company and its shareholders as a whole.

OVERVIEW OF PARTIES

Shenzhen XtalPi is a wholly-owned subsidiary of XtalPi Holdings Limited, whose shares are listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (stock code: 2228). Founded in 2015 by three MIT physicists, Shenzhen XtalPi is an AI-powered and robotics-driven innovative R&D platform based on quantum physics. By integrating quantum physics-based first-principles calculation, AI, high-performance cloud computing, and scalable and standardized robotic automation, it provides drug and material science R&D solutions and services to global and domestic companies in industries such as pharmaceuticals and material sciences (including agricultural technology, energy, new chemicals, and cosmetics). To the best of the Board’s knowledge, information and belief after all reasonable enquiries, Shenzhen XtalPi and its ultimate beneficial owners are each independent third parties of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)).

Founded in 2003, the Company is a R&D-driven international comprehensive pharmaceutical enterprise, focusing on the fields of pediatric medicine, infections, chronic diseases and tumors, with 150 approved drugs and more than 100 drugs under development (including nearly 50 first-class innovative drugs). The Company has ranked among the top 20 in the “Ranking of Comprehensive R&D Strength of Chinese Chemicals Enterprises” for 7 consecutive years, and ranked first among domestic pharmaceutical companies in terms of the number of patents from 2014 to 2023 (44th in the world). The Company has successfully built a HEC drug intelligent discovery platform based on such data assets, including the “HEC-SynAI Drug Synthesis Model” and the “HEC-PharmAI Drug Preparation Model”.

The Board hereby emphasizes that, as of the date of this announcement, the Company and Shenzhen XtalPi have not entered into any formal or legally binding agreement regarding the Strategic Cooperation Agreement. Therefore, the Strategic Cooperation Agreement may or may not be implemented. If the Company enters into any formal agreement in relation to the Strategic Cooperation Agreement, the Company will make a separate announcement in due course in accordance with the Listing Rules.

As the Strategic Cooperation Agreement may or may not proceed, shareholders and potential investors of the Company should exercise caution when dealing in the Company's shares.

By order of the Board
Sunshine Lake Pharma Co., Ltd.
Dr. ZHANG Yingjun
Chairman

Dongguan, the PRC
26 January, 2026

As at the date of this announcement, the executive directors are Dr. ZHANG Yingjun and Dr. LI Wenjia, the non-executive directors are Mr. ZHANG Yushuai, Mr. TANG Xinfu, Mr. ZHU Yingwei, Mr. ZENG Xuebo, Ms. DONG Xiaowei and Ms. WANG Lei, and the independent non-executive directors are Dr. LI Xintian, Dr. MA Dawei, Dr. YIN Hang Hubert, Dr. LIN Aimei and Dr. YE Tao.